The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target.

The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target.
复制标题

DOI:
10.3390/cells12121605
复制
发表时间:
2023-06-11
期刊:
影响因子:
6
通讯作者:
Kurokawa, Manabu
Kurokawa, Manabu
中科院分区:
生物学2区
文献类型:
--
作者:
Feng, William W.;Zuppe, Hannah T.;Kurokawa, Manabu

文献摘要

参考文献

被引文献

相似文献

分化簇36(CD36)是一种细胞表面清道夫受体,在许多不同类型的癌症中发挥关键作用,特别是乳腺癌、脑癌和卵巢癌。虽然它可以说是最广为人知的脂肪酸摄取功能,但它也参与调节细胞黏附、免疫反应和细胞凋亡,这取决于细胞和环境。在这里,我们讨论了CD36在肿瘤生物学中的多方面作用,如它在介导转移、耐药和免疫逃避方面的作用,以展示其作为治疗靶点的潜力。我们还将回顾在临床前研究中针对CD36的现有方法,以及讨论唯一进入后期临床试验的CD36靶向药物VT1021。鉴于CD36在动脉粥样硬化、糖尿病和非酒精性脂肪性肝病等代谢紊乱的病因学中的作用,CD36靶向治疗的临床意义是广泛的,甚至超越了癌症。
Cluster of differentiation 36 (CD36) is a cell surface scavenger receptor that plays critical roles in many different types of cancer, notably breast, brain, and ovarian cancers. While it is arguably most well-known for its fatty acid uptake functions, it is also involved in regulating cellular adhesion, immune response, and apoptosis depending on the cellular and environmental contexts. Here, we discuss the multifaceted role of CD36 in cancer biology, such as its role in mediating metastasis, drug resistance, and immune evasion to showcase its potential as a therapeutic target. We will also review existing approaches to targeting CD36 in pre-clinical studies, as well as discuss the only CD36-targeting drug to advance to late-stage clinical trials, VT1021. Given the roles of CD36 in the etiology of metabolic disorders, such as atherosclerosis, diabetes, and non-alcoholic fatty liver disease, the clinical implications of CD36-targeted therapy are wide-reaching, even beyond cancer.
DOI: 10.1186/s40170-016-0163-7
发表时间: 2017
影响因子: 5.9
作者:
Balaban S;Shearer RF;Lee LS;van Geldermalsen M;Schreuder M;Shtein HC;Cairns R;Thomas KC;Fazakerley DJ;Grewal T;Holst J;Saunders DN;Hoy AJ
通讯作者: Hoy AJ
DOI: 10.1016/j.celrep.2019.11.008
发表时间: 2019-12-10
期刊: CELL REPORTS
影响因子: 8.8
作者:
Feng, William W.;Wilkins, Owen;Kurokawa, Manabu
通讯作者: Kurokawa, Manabu
DOI: 10.1371/journal.pone.0037633
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者:
Geloen A;Helin L;Geeraert B;Malaud E;Holvoet P;Marguerie G
通讯作者: Marguerie G
DOI: 10.1172/jci.insight.147057
发表时间: 2021-09-08
期刊: JCI insight
影响因子: 8
作者:
Daquinag AC;Gao Z;Fussell C;Immaraj L;Pasqualini R;Arap W;Akimzhanov AM;Febbraio M;Kolonin MG
通讯作者: Kolonin MG
DOI: 10.1016/j.cmet.2016.07.003
发表时间: 2016-08-09
期刊: CELL METABOLISM
影响因子: 29
作者:
Corbet, Cyril;Pinto, Adan;Feron, Olivier
通讯作者: Feron, Olivier